Biotechnological potential of Phospholipase D for Loxosceles antivenom development

Autores
Fingermann, Matias; de Roodt, Adolfo Rafael; Cascone, Osvaldo; Miranda, Maria Victoria
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Loxoscelism is one of the most important forms of araneism in South America. The Health Authorities from countries with the highest incidence and longer history in registering loxoscelism cases indicate that specific antivenom should be administered during the first hours after the accident, especially in the presence or at risk of the most severe clinical outcome. Current antivenoms are based on immunoglobulins or their fragments, obtained from plasma of hyperimmunized horses. Antivenom has been produced using the same traditional techniques for more than 120 years. Although the whole composition of the spider venom remains unknown, the discovery and biotechnological production of the phospholipase D enzymes represented a milestone for the knowledge of the physiopathology of envenomation and for the introduction of new innovative tools in antivenom production. The fact that this protein is a principal toxin of the venom opens the possibility of replacing the use of whole venom as an immunogen, an attractive alternative considering the laborious techniques and low yields associated with venom extraction. This challenge warrants technological innovation to facilitate production and obtain more effective antidotes. In this review, we compile the reported studies, examining the advances in the expression and application of phospholipase D as a new immunogen and how the new biotechnological tools have introduced some degree of innovation in this field.
Fil: Fingermann, Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina
Fil: de Roodt, Adolfo Rafael. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Cascone, Osvaldo. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; Argentina
Fil: Miranda, Maria Victoria. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
Materia
ANTIVENOM
BROWN SPIDER
LOXOSCELES
PHOSPHOLIPASE D
SPHINGOMYELINASE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/141219

id CONICETDig_bffc0f76806a054dc070f4e3858686be
oai_identifier_str oai:ri.conicet.gov.ar:11336/141219
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Biotechnological potential of Phospholipase D for Loxosceles antivenom developmentFingermann, Matiasde Roodt, Adolfo RafaelCascone, OsvaldoMiranda, Maria VictoriaANTIVENOMBROWN SPIDERLOXOSCELESPHOSPHOLIPASE DSPHINGOMYELINASEhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1https://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Loxoscelism is one of the most important forms of araneism in South America. The Health Authorities from countries with the highest incidence and longer history in registering loxoscelism cases indicate that specific antivenom should be administered during the first hours after the accident, especially in the presence or at risk of the most severe clinical outcome. Current antivenoms are based on immunoglobulins or their fragments, obtained from plasma of hyperimmunized horses. Antivenom has been produced using the same traditional techniques for more than 120 years. Although the whole composition of the spider venom remains unknown, the discovery and biotechnological production of the phospholipase D enzymes represented a milestone for the knowledge of the physiopathology of envenomation and for the introduction of new innovative tools in antivenom production. The fact that this protein is a principal toxin of the venom opens the possibility of replacing the use of whole venom as an immunogen, an attractive alternative considering the laborious techniques and low yields associated with venom extraction. This challenge warrants technological innovation to facilitate production and obtain more effective antidotes. In this review, we compile the reported studies, examining the advances in the expression and application of phospholipase D as a new immunogen and how the new biotechnological tools have introduced some degree of innovation in this field.Fil: Fingermann, Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; ArgentinaFil: de Roodt, Adolfo Rafael. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Cascone, Osvaldo. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; ArgentinaFil: Miranda, Maria Victoria. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; ArgentinaElsevier2020-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/141219Fingermann, Matias; de Roodt, Adolfo Rafael; Cascone, Osvaldo; Miranda, Maria Victoria; Biotechnological potential of Phospholipase D for Loxosceles antivenom development; Elsevier; Toxicon: X; 6; 6-2020; 1-92590-1710CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S259017102030014Xinfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.toxcx.2020.100036info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:22:08Zoai:ri.conicet.gov.ar:11336/141219instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:22:09.188CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Biotechnological potential of Phospholipase D for Loxosceles antivenom development
title Biotechnological potential of Phospholipase D for Loxosceles antivenom development
spellingShingle Biotechnological potential of Phospholipase D for Loxosceles antivenom development
Fingermann, Matias
ANTIVENOM
BROWN SPIDER
LOXOSCELES
PHOSPHOLIPASE D
SPHINGOMYELINASE
title_short Biotechnological potential of Phospholipase D for Loxosceles antivenom development
title_full Biotechnological potential of Phospholipase D for Loxosceles antivenom development
title_fullStr Biotechnological potential of Phospholipase D for Loxosceles antivenom development
title_full_unstemmed Biotechnological potential of Phospholipase D for Loxosceles antivenom development
title_sort Biotechnological potential of Phospholipase D for Loxosceles antivenom development
dc.creator.none.fl_str_mv Fingermann, Matias
de Roodt, Adolfo Rafael
Cascone, Osvaldo
Miranda, Maria Victoria
author Fingermann, Matias
author_facet Fingermann, Matias
de Roodt, Adolfo Rafael
Cascone, Osvaldo
Miranda, Maria Victoria
author_role author
author2 de Roodt, Adolfo Rafael
Cascone, Osvaldo
Miranda, Maria Victoria
author2_role author
author
author
dc.subject.none.fl_str_mv ANTIVENOM
BROWN SPIDER
LOXOSCELES
PHOSPHOLIPASE D
SPHINGOMYELINASE
topic ANTIVENOM
BROWN SPIDER
LOXOSCELES
PHOSPHOLIPASE D
SPHINGOMYELINASE
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Loxoscelism is one of the most important forms of araneism in South America. The Health Authorities from countries with the highest incidence and longer history in registering loxoscelism cases indicate that specific antivenom should be administered during the first hours after the accident, especially in the presence or at risk of the most severe clinical outcome. Current antivenoms are based on immunoglobulins or their fragments, obtained from plasma of hyperimmunized horses. Antivenom has been produced using the same traditional techniques for more than 120 years. Although the whole composition of the spider venom remains unknown, the discovery and biotechnological production of the phospholipase D enzymes represented a milestone for the knowledge of the physiopathology of envenomation and for the introduction of new innovative tools in antivenom production. The fact that this protein is a principal toxin of the venom opens the possibility of replacing the use of whole venom as an immunogen, an attractive alternative considering the laborious techniques and low yields associated with venom extraction. This challenge warrants technological innovation to facilitate production and obtain more effective antidotes. In this review, we compile the reported studies, examining the advances in the expression and application of phospholipase D as a new immunogen and how the new biotechnological tools have introduced some degree of innovation in this field.
Fil: Fingermann, Matias. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina
Fil: de Roodt, Adolfo Rafael. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Cascone, Osvaldo. Ministerio de Salud de la Nación. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud "Doctor Carlos G. Malbrán". Instituto Nacional de Producción de Biológicos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; Argentina
Fil: Miranda, Maria Victoria. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología Industrial y Biotecnología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Nanobiotecnología. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Nanobiotecnología; Argentina
description Loxoscelism is one of the most important forms of araneism in South America. The Health Authorities from countries with the highest incidence and longer history in registering loxoscelism cases indicate that specific antivenom should be administered during the first hours after the accident, especially in the presence or at risk of the most severe clinical outcome. Current antivenoms are based on immunoglobulins or their fragments, obtained from plasma of hyperimmunized horses. Antivenom has been produced using the same traditional techniques for more than 120 years. Although the whole composition of the spider venom remains unknown, the discovery and biotechnological production of the phospholipase D enzymes represented a milestone for the knowledge of the physiopathology of envenomation and for the introduction of new innovative tools in antivenom production. The fact that this protein is a principal toxin of the venom opens the possibility of replacing the use of whole venom as an immunogen, an attractive alternative considering the laborious techniques and low yields associated with venom extraction. This challenge warrants technological innovation to facilitate production and obtain more effective antidotes. In this review, we compile the reported studies, examining the advances in the expression and application of phospholipase D as a new immunogen and how the new biotechnological tools have introduced some degree of innovation in this field.
publishDate 2020
dc.date.none.fl_str_mv 2020-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/141219
Fingermann, Matias; de Roodt, Adolfo Rafael; Cascone, Osvaldo; Miranda, Maria Victoria; Biotechnological potential of Phospholipase D for Loxosceles antivenom development; Elsevier; Toxicon: X; 6; 6-2020; 1-9
2590-1710
CONICET Digital
CONICET
url http://hdl.handle.net/11336/141219
identifier_str_mv Fingermann, Matias; de Roodt, Adolfo Rafael; Cascone, Osvaldo; Miranda, Maria Victoria; Biotechnological potential of Phospholipase D for Loxosceles antivenom development; Elsevier; Toxicon: X; 6; 6-2020; 1-9
2590-1710
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S259017102030014X
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.toxcx.2020.100036
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082617003212800
score 13.22299